December 9, 2021 5:07pm

Luckily, I wrote “Sell into Strength” yesterday to “cash out beats being cashiered’ and, a “show me the money” session’ – it came true

The Biostage (BSTG) Chronicles: Thursday closed $0.00 with 26 shares traded after Wednesday closed down -$0.34 with 160 shares traded, Tuesday closed down -$0.20 with 2,965 shares traded, Monday closed +$0.21 to $3.21 with 6,466 shares traded. What NO “pump and promote” today; does the pattern of months and months of trading volume and pricing pushes - express a time for the SEC to take a closer look?

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price targets.

The Dow closed DOWN -0.06 points (-0.00%); the S&P closed DOWN -33.76 points (-0.72%) while the Nasdaq closed DOWN -269.32 points (-1.71%)

 

Henry’omics:

Indexes were flattened on Thursday, after the major averages posted a third (3rd) straight day of gains and traders took a pause as they awaited economic data especially the inflation “reading” on Friday.

Stocks gave back some of their gains from recent days, with the moves higher spurred by the belief that the omicron variant of Covid looks less severe than earlier forms. <CNBC>

 

Economic data Docket: The Labor Department reported initial claims for unemployment insurance totaled 184,000, compared to the 211,000 estimate.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Thursday opened negative at 4 ups/20 downs, 1 flat and 1 acquired, stayed positive at the mid-day at 3/30, 1 flat and 1 acquired, ending with a negative close of 0 up/33 downs, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “a negative indication had warned me that an acknowledged drop continued to lurk. Especially a very weak aftermarket after the Nasdaq registered a third day of gains” … https://www.regmedinvestors.com/articles/12218

 

The Biostage (BSTG) Chronicles: Thursday closed $0.00 with 26 shares traded after Wednesday closed down -$0.34 with 160 shares traded after Tuesday closed down -$0.20 with 2,965 shares traded, Monday closed +$0.21 to $3.21 with 6,466 shares traded, Friday closed flat with 0 shares traded, and last Thursday closed up +$0.07 with 3,527 shares traded

  • What NO “pump and promote” today; does the pattern of months and months of trading volume express a time for the SEC to take a closer look?

 

Key Metric - volume

Sector volume LOW with 0 of the 0-upside having higher than the 3-month average volume with LOW volume of 9 of 33-downside having higher than the 3-month average volume;

 

Jumping with share pricing momentum (0 of 0):

  • NONE

Hammered in today’s market (10 of 33):

  • ReNeuron (RENE.L -$6.00),
  • Alnylam Pharmaceuticals (ALNY -$4.45 after Wednesday’s -$3.36, Tuesday’s +$3.28 and Monday’s +$5.64),
  • Intellia Therapeutics (NTLA -$4.38 after Wednesday’s -$0.67, Tuesday’s +$16.34 and Monday’s -$0.27),
  • CRISPR Therapeutics (CRSP -$3.95 after Wednesday’s +$1.02, Tuesday’s +$7.27 and Monday’s +$1.03),
  • Fate Therapeutics (FATE -$2.71 after Wednesday’s +$1.37, Tuesday’s +$6.75 and Monday’s -$0.16),
  • Ultragenyx (RARE -$2.52 after Wednesday’s -$3.43, Tuesday’s +$5.55 and Monday’s +$2.88),
  • Vericel (VCEL -$2.11 after Wednesday’s +$0.94, Tuesday’s +$2.24 and Monday’s +$1.81),
  • Ionis Pharmaceuticals (IONS -$1.93 after Wednesday’s +$1.64, Tuesday’s +$3.07 and Monday’s +$1.11),
  • BioLife Solutions (BLFS -$1.58),
  • Sage Therapeutics (SAGE -$1.47 after Wednesday’s +$0.52 and Tuesday’s +$2.11),

Closing Flat:

  • 1 – Biostage (BSTG) and -1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -2.07% and XBI closed down -4.21%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +1.68 points or +8.44% at 21.58

 

December, the second month of Q4/21:

Thursday closed negative with 0 incliners, 33 decliners, 1 flat and 1 acquired

Wednesday closed positive with 24 incliners, 7 decliners, 3 flats and 1 acquired

Tuesday closed positive with 29 incliner, 4 decliners, 1 flat and 1 acquired

Monday (12/6) closed positive with 25 incliner, 9 decliners and 1 acquired

 

The BOTTOM LINE:  Knew it yesterday – I warned the cratering was coming and was RIGHT yet gain.

Yesterday, the session to “show me the money” … hit the nail on its head.

Tread lightly, tax selling is upon us!

In any case, I have continued to write … don’t ramp exposure at the current levels.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.